These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 20716957)
21. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Milenic DE; Garmestani K; Brady ED; Albert PS; Ma D; Abdulla A; Brechbiel MW Clin Cancer Res; 2004 Dec; 10(23):7834-41. PubMed ID: 15585615 [TBL] [Abstract][Full Text] [Related]
22. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Olafsen T; Kenanova VE; Sundaresan G; Anderson AL; Crow D; Yazaki PJ; Li L; Press MF; Gambhir SS; Williams LE; Wong JY; Raubitschek AA; Shively JE; Wu AM Cancer Res; 2005 Jul; 65(13):5907-16. PubMed ID: 15994969 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors. Orlova A; Rosik D; Sandström M; Lundqvist H; Einarsson L; Tolmachev V Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):314-23. PubMed ID: 17464277 [TBL] [Abstract][Full Text] [Related]
24. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [ Chan C; Fonge H; Lam K; Reilly RM Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737 [TBL] [Abstract][Full Text] [Related]
25. HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. Nayak TK; Garmestani K; Milenic DE; Baidoo KE; Brechbiel MW PLoS One; 2011 Mar; 6(3):e18198. PubMed ID: 21464917 [TBL] [Abstract][Full Text] [Related]
26. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates. Razumienko EJ; Scollard DA; Reilly RM J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164 [TBL] [Abstract][Full Text] [Related]
27. Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody. Shin IS; Lee SM; Kim HS; Yao Z; Regino C; Sato N; Cheng KT; Hassan R; Campo MF; Albone EF; Choyke PL; Pastan I; Paik CH Nucl Med Biol; 2011 Nov; 38(8):1119-27. PubMed ID: 21741258 [TBL] [Abstract][Full Text] [Related]
28. Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma. Nayak TK; Garmestani K; Baidoo KE; Milenic DE; Brechbiel MW J Nucl Med; 2010 Jun; 51(6):942-50. PubMed ID: 20484421 [TBL] [Abstract][Full Text] [Related]
29. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts. Costantini DL; McLarty K; Lee H; Done SJ; Vallis KA; Reilly RM J Nucl Med; 2010 Jul; 51(7):1084-91. PubMed ID: 20554744 [TBL] [Abstract][Full Text] [Related]
30. Pretargeted tumour imaging with streptavidin immunoconjugates of monoclonal antibody CC49 and 111In-DTPA-biocytin. Alvarez-Diez TM; Polihronis J; Reilly RM Nucl Med Biol; 1996 May; 23(4):459-66. PubMed ID: 8832700 [TBL] [Abstract][Full Text] [Related]
31. (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW Mol Cancer Ther; 2012 Mar; 11(3):639-48. PubMed ID: 22238365 [TBL] [Abstract][Full Text] [Related]
32. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates. Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962 [TBL] [Abstract][Full Text] [Related]
33. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225. Wen X; Wu QP; Ke S; Ellis L; Charnsangavej C; Delpassand AS; Wallace S; Li C J Nucl Med; 2001 Oct; 42(10):1530-7. PubMed ID: 11585869 [TBL] [Abstract][Full Text] [Related]
34. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729 [TBL] [Abstract][Full Text] [Related]
35. Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts. Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196891 [TBL] [Abstract][Full Text] [Related]
36. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Pastuskovas CV; Mundo EE; Williams SP; Nayak TK; Ho J; Ulufatu S; Clark S; Ross S; Cheng E; Parsons-Reponte K; Cain G; Van Hoy M; Majidy N; Bheddah S; dela Cruz Chuh J; Kozak KR; Lewin-Koh N; Nauka P; Bumbaca D; Sliwkowski M; Tibbitts J; Theil FP; Fielder PJ; Khawli LA; Boswell CA Mol Cancer Ther; 2012 Mar; 11(3):752-62. PubMed ID: 22222630 [TBL] [Abstract][Full Text] [Related]
38. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy. Pan MH; Gao DW; Feng J; He J; Seo Y; Tedesco J; Wolodzko JG; Hasegawa BH; Franc BL Mol Imaging Biol; 2009; 11(3):159-66. PubMed ID: 19034582 [TBL] [Abstract][Full Text] [Related]
39. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Shah C; Miller TW; Wyatt SK; McKinley ET; Olivares MG; Sanchez V; Nolting DD; Buck JR; Zhao P; Ansari MS; Baldwin RM; Gore JC; Schiff R; Arteaga CL; Manning HC Clin Cancer Res; 2009 Jul; 15(14):4712-21. PubMed ID: 19584166 [TBL] [Abstract][Full Text] [Related]
40. Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Parry R; Schneider D; Hudson D; Parkes D; Xuan JA; Newton A; Toy P; Lin R; Harkins R; Alicke B; Biroc S; Kretschmer PJ; Halks-Miller M; Klocker H; Zhu Y; Larsen B; Cobb RR; Bringmann P; Roth G; Lewis JS; Dinter H; Parry G Cancer Res; 2005 Sep; 65(18):8397-405. PubMed ID: 16166318 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]